THE MOST FORMIDABLE
HEALTH CHALLENGES DON'T
FALL NEATLY IN ONE BUCKET

We are focused on addressing a broad range of serious medical conditions including ophthalmology, cancer, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases. Our industry-leading research and development engine enables us to develop all potential drug candidates from within our own labs.

  • 14
    antibodies in clinical
    trials across multiple
    therapeutic areas
  • 100%
    of drug candidates
    invented and
    developed in-house
  • CARDIOVASCULAR AND
    METABOLISM

  • INFECTIOUS DISEASES

  • Cardiovascular and metabolic disorders encompass a large number of diseases, including coronary artery disease and diabetes. Our current clinical programs focus on treating cardiovascular disease, the number one cause of morbidity and mortality in the United States and other developed countries, and on muscle-growth disorders.

  • We are advancing new approaches to address serious infections that impact vulnerable populations.

    These include infections by Respiratory Syncytial Virus (RSV), a serious and contagious virus that infects the lungs and respiratory tract and is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under the age of one.

    In an increasingly interconnected world, infectious diseases are able to spread

    more quickly than in the past, enhancing their threat to global health and elevating the need for new treatments that are safe, effective and easily deployed. We are leveraging our proprietary technologies to create superior fully human monoclonal antibodies, with the goal of addressing a number of common and newly emerging infectious diseases, such as Ebola and Middle East respiratory syndrome (MERS).

  • INFLAMMATION AND
    IMMUNOLOGY

  • ONCOLOGY

  • Inflammation is the body's natural protective response against injury and infections, including those caused by bacteria and viruses.

    But inflammation can also occur when the immune system triggers an inappropriate inflammatory response to the body's own cells, or responds excessively to external irritants such as pollen or certain foods. This inflammatory response is usually accompanied by the overproduction of certain proteins called cytokines, including interleukins, and can result in chronic and

    debilitating disease conditions such as rheumatoid arthritis, atopic dermatitis or asthma.

    One therapeutic approach is to block the actions of the cytokines that play a role in the development of these diseases.

  • Despite decades of progress, cancer still remains one of the world's most serious health problems.

    Our approach to cancer is multifaceted:

    • Immuno-Oncology works by unleashing the body's own immune system to eliminate or control cancer. We believe the most successful approaches will combine multiple innovative therapies acting on different pathways and targets, both in the patient's tumor as well as in their immune response, to precisely tailor the best treatments to the individual. We are currently exploring multiple approaches, including checkpoint inhibitors and bispecific antibodies
    • Anti-angiogenesis is the disruption of the blood flow to tumors by inhibiting the formation of new blood vessels. We continue to investigate the potential of novel approaches to inhibit angiogenesis, as well as the possibility of
    • combination approaches that benefit from blocking angiogenesis and altering the tumor microenvironment
    • Antibody drug conjugates (ADCs) are novel combination therapies that enable the selective killing of cancer cells by joining cancer-targeting antibodies with a highly potent chemotherapy, or "warhead." ADCs are designed to take advantage of both the specificity of antibodies and the cancer-killing power of cytotoxic agents
    • Cancer cell dependencies are mutant or aberrant signaling pathways that are required by cancer cells for growth and survival, as a result of their specific oncogenic mutations. We are exploring novel antibody technologies to better target cancer cell dependencies
  • OPHTHALMOLOGY

  • PAIN

  • We have a long-standing commitment to the treatment of serious, vision-threatening diseases.

    Our R&D programs target a number of mechanisms in retinal diseases in unique combinations with anti-Vascular Endothelial Growth Factor (VEGF) therapy, which employs Regeneron's proprietary Trap technology and is currently the standard-of-care for a number of retinal conditions. The VEGF protein is necessary to stimulate the formation of blood vessels that supply nutrients to tissues. However, excessive VEGF production can lead to retinal conditions in which blood vessels grow abnormally, become fragile, and vision is threatened due to fluid and blood leaking into surrounding tissue. If untreated, the swelling can damage cells, create blind spots in central vision and lead to permanent vision loss.

    While many patients have success with current anti-VEGF therapies, additional factors may also contribute to vascular dysfunction. Our ongoing programs are

    evaluating antibodies that target Platelet Derived Growth Factor Receptor Beta (PDGFR-beta) and angiopoietin2 (ANG2) in combination with anti-VEGF therapy.

    Discovered by scientists at Regeneron, angiopoietins are a family of vascular-specific growth factors. Preclinical data demonstrates that angiopoietins act together with the VEGF family to promote the formation and maturation of blood and lymphatic vessels in the eye. ANG2 and VEGF together therefore have the potential to influence the pathological development of new blood vessels and the permeability of blood vessel walls in certain diseases of the eye.

  • We are advancing new non-opioid treatment options for patients suffering from a range of chronic pain conditions, including osteoarthritis pain and chronic back pain.

    Many of these patients are currently treated with opioid medicines, which can often come with unwanted side effects and the potential for abuse. We are leading the discovery and characterization of a new class of proteins, called

    neurotrophins, which promote the growth of nerve cells. Members of this family of proteins include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and others.

  • RARE DISEASES

  • Our long history and commitment to genetics-based medicine, which began well before our first FDA-approved treatment for an ultra-rare condition, is evident today through the cutting-edge research being done by both the Regeneron Genetics Center and our Research and Development groups.

    We believe that following sound and innovative science leads to important new treatments, and we pursue this science regardless of the commercial opportunity or size of the patient population. We leverage currently available research tools and create our own, which are extremely well-suited to reveal the genetics and biology of monogenic diseases (diseases caused by a mutation in a single gene). These investigations provide insight into novel pathways that may lead to the discovery and development of new medicines.

    Our approved and investigational medicines target a number of rare diseases:

    • Cryopyrin-Associated Periodic Syndromes (CAPS): Our first FDA-approved drug addresses this set of rare yet closely related auto-inflammatory diseases
    • Heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH): We have an approved treatment for certain patients with (HeFH), and are studying an investigational ANGPTL3 antibody in (HoFH). People with HeFH or HoFH have an inherited form of high cholesterol and are unable to process the body's natural supply of
    • cholesterol in the liver, which researchers believe lead to very high levels of LDL-C that can block arteries (atherosclerosis) and lead to a heart attack or stroke.
    • Fibrodysplasia Ossificans Progressiva (FOP): Scientists in our Skeletal Diseases Therapeutic Focus Area have been investigating FOP and related conditions for nearly 20 years. FOP is a progressive, severely disabling and ultimately fatal disease in which muscles, ligaments, tendons and other connective tissues are transformed into bone. We recently discovered a new way to potentially treat this disease, and are conducting clinical studies of our Activin A antibody as a potential therapy

    We are proud members of the NORD Corporate Counsel and work to support many rare disease advocacy organizations.

  • CARDIOVASCULAR AND
    METABOLISM

  • Cardiovascular and metabolic disorders encompass a large number of diseases, including coronary artery disease and diabetes. Our current clinical programs focus on treating cardiovascular disease, the number one cause of morbidity and mortality in the United States and other developed countries, and on muscle-growth disorders.

  • INFECTIOUS DISEASES

  • We are advancing new approaches to address serious infections that impact vulnerable populations.

    These include infections by Respiratory Syncytial Virus (RSV), a serious and contagious virus that infects the lungs and respiratory tract and is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under the age of one.

    In an increasingly interconnected world, infectious diseases are able to spread more quickly than in the past, enhancing their threat to global health and elevating the need for new treatments that are safe, effective and easily deployed. We are leveraging our proprietary technologies to create superior fully human monoclonal antibodies, with the goal of addressing a number of common and newly emerging infectious diseases, such as Ebola and Middle East respiratory syndrome (MERS).

  • INFLAMMATION AND
    IMMUNOLOGY

  • Inflammation is the body's natural protective response against injury and infections, including those caused by bacteria and viruses.

    But inflammation can also occur when the immune system triggers an inappropriate inflammatory response to the body's own cells, or responds excessively to external irritants such as pollen or certain foods. This inflammatory response is usually accompanied by the overproduction of certain proteins called cytokines, including interleukins, and can result in chronic and debilitating disease conditions such as rheumatoid arthritis, atopic dermatitis or asthma.

    One therapeutic approach is to block the actions of the cytokines that play a role in the development of these diseases.

  • ONCOLOGY

  • Despite decades of progress, cancer still remains one of the world's most serious health problems.

    Our approach to cancer is multi-faceted:

    • Immuno-Oncology works by unleashing the body's own immune system to eliminate or control cancer. We believe the most successful approaches will combine multiple innovative therapies acting on different pathways and targets, both in the patient's tumor as well as in their immune response, to precisely tailor the best treatments to the individual. We are currently exploring multiple approaches, including checkpoint inhibitors and bispecific antibodies
    • Anti-angiogenesis is the disruption of the blood flow to tumors by inhibiting the formation of new blood vessels. We continue to investigate the potential of novel approaches to inhibit angiogenesis, as well as the possibility of combination approaches that benefit from blocking angiogenesis and altering the tumor microenvironment
    • Antibody drug conjugates (ADCs) are novel combination therapies that enable the selective killing of cancer cells by joining cancer-targeting antibodies with a highly potent chemotherapy, or "warhead." ADCs are designed to take advantage of both the specificity of antibodies and the cancer-killing power of cytotoxic agents
    • Cancer cell dependencies are mutant or aberrant signaling pathways that are required by cancer cells for growth and survival, as a result of their specific oncogenic mutations. We are exploring novel antibody technologies to better target cancer cell dependencies
  • OPHTHALMOLOGY

  • We have a long-standing commitment to the treatment of serious, vision-threatening diseases.

    Our R&D programs target a number of mechanisms in retinal diseases in unique combinations with anti-Vascular Endothelial Growth Factor (VEGF) therapy, which employs Regeneron's proprietary "Trap" technology and is currently the standard-of-care for a number of retinal conditions. The VEGF protein is necessary to stimulate the formation of blood vessels that supply nutrients to tissues. However, excessive VEGF production can lead to retinal conditions in which blood vessels grow abnormally, become fragile, and vision is threatened due to fluid and blood leaking into surrounding tissue. If untreated, the swelling can damage cells, create blind spots in central vision and lead to permanent vision loss.

    While many patients have success with current anti-VEGF therapies, additional factors may also contribute to vascular dysfunction. Our ongoing programs are evaluating antibodies that target Platelet Derived Growth Factor Receptor Beta (PDGFR-beta) and angiopoietin2 (ANG2) in combination with anti-VEGF therapy.

    Discovered by scientists at Regeneron, angiopoietins are a family of vascular-specific growth factors. Preclinical data demonstrates that angiopoietins act together with the VEGF family to promote the formation and maturation of blood and lymphatic vessels in the eye. ANG2 and VEGF together therefore have the potential to influence the pathological development of new blood vessels and the permeability of blood vessel walls in certain diseases of the eye.

  • PAIN

  • We are advancing new non-opioid treatment options for patients suffering from a range of chronic pain conditions, including osteoarthritis pain and chronic back pain.

    Many of these patients are currently treated with opioid medicines, which can often come with unwanted side effects and the potential for abuse. We are leading the discovery and characterization of a new class of proteins, called neurotrophins, which promote the growth of nerve cells. Members of this family of proteins include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and others.

  • RARE DISEASES

  • Our long history and commitment to genetics-based medicine, which began well before our first FDA-approved treatment for an ultra-rare condition, is evident today through the cutting-edge research being done by both the Regeneron Genetics Center and our Research and Development groups.

    We believe that following sound and innovative science leads to important new treatments, and we pursue this science regardless of the commercial opportunity or size of the patient population. We leverage currently available research tools and create our own, which are extremely well-suited to reveal the genetics and biology of monogenic diseases (diseases caused by a mutation in a single gene). These investigations provide insight into novel pathways that may lead to the discovery and development of new medicines.

    Our approved and investigational medicines target a number of rare diseases:

    • Cryopyrin-Associated Periodic Syndromes (CAPS): Our first FDA-approved drug addresses this set of rare yet closely related auto-inflammatory diseases
    • Heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH): We have an approved treatment for certain patients with (HeFH), and are studying an investigational ANGPTL3 antibody in (HoFH). People with HeFH or HoFH have an inherited form of high cholesterol and are unable to process the body's natural supply of cholesterol in the liver, which researchers believe lead to very high levels of LDL-C that can block arteries (atherosclerosis) and lead to a heart attack or stroke.
    • Fibrodysplasia Ossificans Progressiva (FOP): Scientists in our Skeletal Diseases Therapeutic Focus Area have been investigating FOP and related conditions for nearly 20 years. FOP is a progressive, severely disabling and ultimately fatal disease in which muscles, ligaments, tendons and other connective tissues are transformed into bone. We recently discovered a new way to potentially treat this disease, and are conducting clinical studies of our Activin A antibody as a potential therapy

    We are proud members of the NORD Corporate Counsel and work to support many rare disease advocacy organizations.

Learn more about Investigator Initiated Studies

In 1980, a young Aynur Hermann sat transfixed in front of the television at her home in Germany as Carl Sagan explored the bounds of the universe in the popular Cosmos: A Personal Voyage television series. "I was completely hypnotized," she said. "I knew then that I could only work in science, and nothing else."

Read Aynur's story